PLYMOUTH MEETING, PA – Jeffrey Dierks, the Chief Commercial Officer of Harmony Biosciences Holdings , Inc. (NASDAQ:), has sold 11,979 shares of the company’s common stock on March 15, 2024, for a total value of approximately $383,328, at prices ranging from $32.00 to $32.06 per share, according to a recent SEC filing.
The transactions were conducted under a prearranged 10b5-1 trading plan, which allows company insiders to set up a predetermined plan for buying or selling stocks at a time when they are not in possession of material non-public information. The sales took place through a series of transactions, and Dierks has agreed to provide additional details about the prices per share upon request.
On the same date, Dierks also acquired 11,979 shares of Harmony Biosciences’ common stock at a price of $8.22 per share, totaling $98,467. These shares were not part of the sale and represent a separate transaction.
In addition to the common stock transactions, Dierks exercised options for 2,335 shares and another set of options for 9,644 shares of Harmony Biosciences’ stock. Both sets of stock options had an exercise price of $8.22 per share. Following these transactions, Dierks no longer holds any shares from the first option exercise and retains 4,869 shares from the second. The stock options vested in five equal annual installments, with the first set beginning on October 1, 2019, and the second set on March 1, 2021.
Harmony Biosciences Holdings, Inc. specializes in pharmaceutical preparations and is based in Plymouth Meeting, Pennsylvania. The company’s business phone is (484) 539-9800.
InvestingPro Insights
As Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) navigates the market, recent activity by insiders such as Jeffrey Dierks can be of interest to investors. While insider transactions are not always indicative of company performance, they can offer insights into how those closest to the company view its prospects.
InvestingPro data highlights a robust financial picture for Harmony Biosciences, with a significant 32.93% revenue growth over the last twelve months as of Q4 2023, and a gross profit margin of 79.17% indicating efficient operations. The company’s strong performance is further evidenced by an operating income margin of 32.99%, showcasing effective management and profitability potential.
One of the InvestingPro Tips suggests that management has been actively involved in share buybacks, which could signal confidence in the company’s value and future. Moreover, Harmony Biosciences operates with a moderate level of debt, which can be an encouraging sign for investors looking for a potentially stable investment. It’s also noteworthy that analysts predict the company will be profitable this year, which aligns with the company’s recent financial achievements.
For those interested in a deeper dive into Harmony Biosciences’ financials and future outlook, InvestingPro offers additional tips and metrics. There are currently 7 more InvestingPro Tips available, which can be accessed at https://www.investing.com/pro/HRMY. To enrich your investing strategy with this comprehensive analysis, use the coupon code PRONEWS24 for an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here
